Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2020 1
2021 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean fengli yu (19 results)?
Hengli() Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
Liao L, Liu Q, Cong H, Xu Z, Li E, Weng Z, Jiang H, Liu B, Huang X, Xia S, Wen W, Wu J, Shi G, Wang Y, Li P, Yu Y, Fang Z, Zheng J, Tian Y, Shang D, Li H, Huang Z, Zhou L, Xiao Y, Zhang Y, Wang J, Zhang X, Zhang P, Wang D, Zhang X, Xie K, Wang B, Ma L, Tian X, Chen L, Dong J. Liao L, et al. Front Pharmacol. 2022 Feb 18;13:840695. doi: 10.3389/fphar.2022.840695. eCollection 2022. Front Pharmacol. 2022. PMID: 35250586 Free PMC article.
Objective: To evaluate the efficacy and safety of Hengli() Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with overactive bladder. ...An increased post-void residual urine volume, dysuria, and urinary tract infection represented adverse events (AEs) in t …
Objective: To evaluate the efficacy and safety of Hengli() Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with ove …
Influence of Goniotomy Size on Treatment Safety and Efficacy for Primary Open-Angle Glaucoma: A Multicenter Study.
Zhang Y, Yu P, Zhang Y, Sugihara K, Zhu X, Zhang Y, Yang X, Li X, Liu Y, Zhang H, Yan X, Zhang H, Lin F, Song Y, Gao X, Yuan H, Tang G, Zhou W, Fan S, Dang G, Tang L, Chen W, Wang N, Park KH, Barton K, Aung T, Lam DSC, Weinreb RN, Xie L, Tanito M, Zeng L, Zhang X; PVP Study Group. Zhang Y, et al. Am J Ophthalmol. 2023 Dec;256:118-125. doi: 10.1016/j.ajo.2023.08.002. Epub 2023 Aug 11. Am J Ophthalmol. 2023. PMID: 37573988 Clinical Trial.